Technology
Health
Biotechnology

Trillium Therapeutics

$0.70
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.0479 (7.23%) Today
-$0.01 (-1.41%) After Hours

Why Robinhood?

You can buy or sell TRIL and other stocks, options, ETFs, and crypto commission-free!

About

Trillium Therapeutics Inc. Common Shares, also called Trillium Therapeutics, is a clinical stage immuno-oncology company, which engages in the development of innovative therapies for the treatment of cancer. Read More Its pipeline is comprised of TTI-621, TTI-622, and TTI-2341(EGFR Inhibitor). The company was founded on March 31, 2004 and is headquartered in Toronto, Canada.

Employees
60
Headquarters
Mississauga, Ontario
Founded
2004
Market Cap
9.73M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
191.16K
High Today
$0.717
Low Today
$0.639
Open Price
$0.6618
Volume
885.29K
52 Week High
$8.10
52 Week Low
$0.55

Collections

Technology
Health
Biotechnology
Therapy
Medical
Cancer Prevention
2014 IPO
Canada

News

Simply Wall StMar 8

The Trillium Therapeutics (TSE:TRIL) Share Price Is Down 95% So Some Shareholders Are Rather Upset

Long term investing works well, but it doesn’t always work for each individual stock. We really hate to see fellow investors lose their hard-earned money. Spare a thought for those who held Trillium Therapeutics Inc. (TSE:TRIL) for five whole years – as the share price tanked 95%. And it’s not just long term holders hurting, because the stock is down 90% in the last year. Shareholders have had an even rougher run lately, with the share price down 67% in the last 90 days. We really hope anyone holding throu...

704
Markets InsiderFeb 22

Trillium Announces Pricing of US$15 Million Public Offering of Common Share Units and Series II Non-Voting Convertible First Preferred Share Units

TORONTO, Feb. 22, 2019 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has priced its previously announced underwritten public offering of 6,550,000 common share units (the “Common Share Units”) of the Company and 12,200,000 Series II Non-Voting Convertible First Preferred Share units (the “Series II First Preferred Share Units”) of th...

861
MarketBeatFeb 22

Stock Price, News, & Analysis for Trillium Therapeutics

Trillium Therapeutics Inc is a Canada-based clinical stage immuno-oncology company developing therapies for the treatment of cancer.

15

Earnings

Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
Actual
Available Mar 11, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.